Skip to content
value.today

Monopar Therapeutics Inc.

MNPR
$487 Mmarket cap on Oct 28, 2026+8014.0% since Jan 2024
Compare
World rank
#12,670
Revenue
$0 M
For year ending December-2025
value.today research
Net income
$-14 M
value.today research
Employees
—

Monopar Therapeutics Inc. in brief

Monopar Therapeutics Inc. is a listed company in the Biotechnology industry, based in Wilmette, Illinois, USA. Its market value was $487 M on 28 October 2026, which makes it the 12,670th largest listed company in the world and the 2,553rd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $14 M. Chandler Robinson is its chief executive. Its shares trade under the symbol MNPR (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Monopar Therapeutics Inc.

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company developing an innovative treatment for Wilson disease and novel radiopharmaceuticals for oncology. Our Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Our radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of advanced cancers, that express urokinase plasminogen activator receptor.

We build our drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics, leveraging our scientific and clinical expertise to reduce risk and accelerate development.

From the company's annual report filed with the US SEC: read the report

Monopar Therapeutics Inc. timeline

2 events, 2015–2018
  1. 2015
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2018
  4. •
    Legal Entity Identifier issued
    LEI 549300QJFAI7L6YHKG83 registered.

Events of Monopar Therapeutics Inc. from SEC EDGAR and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$205 M$410 M$615 M$820 M2023202420252026

World rank over time

▲ up 14,770 places since 2022
2022-01-07: #27475#27,47520222022-12-25: #27422#27,42220222023-07-30: #31712#31,71220232024-01-05: #32064#32,06420242026-03-08: #7780#7,78020262026-08-01: #10497#10,49720262026-10-28: #12705#12,7052026

Rank in USA: #5,012 (Jan 2022) · #5,056 (Dec 2022) · #5,458 (Jul 2023) · #4,604 (Jan 2024) · #1,381 (Mar 2026) · #2,270 (Aug 2026) · #2,556 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
3.5×
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-10.0%
Liabilities / assets
2.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-3M—FY18Fiscal year ending Dec 2019: revenue —, net income $-4M—FY19Fiscal year ending Dec 2020: revenue —, net income $-6M—FY20Fiscal year ending Dec 2021: revenue —, net income $-9M—FY21Fiscal year ending Dec 2022: revenue —, net income $-11M—FY22Fiscal year ending Dec 2023: revenue —, net income $-8M—FY23Fiscal year ending Dec 2024: revenue —, net income $-16M—FY24Fiscal year ending Dec 2025: revenue —, net income $-14M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-17M$-14M—
Dec 2024——$-16M$-16M—
Dec 2023——$-9M$-8M—
Dec 2022——$-11M$-11M—
Dec 2021——$-9M$-9M—
Dec 2020——$-7M$-6M—
Dec 2019——$-4M$-4M—
Dec 2018——$-3M$-3M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-12M————
Dec 2024$-6M————
Dec 2023$-8M————
Dec 2022$-7M————
Dec 2021$-7M——$-0.73—
Dec 2020$-5M——$-0.58—
Dec 2019$-3M——$-0.45—
Dec 2018$-3M——$-0.35—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-11M—Dec ’24Three months to Mar 2025: revenue —, net income $-3M—Mar ’25Three months to Jun 2025: revenue —, net income $-2M—Jun ’25Three months to Sep 2025: revenue —, net income $-3M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-5M—Dec ’25Three months to Mar 2026: revenue —, net income $-4M—Mar ’26Three months to Jun 2026: revenue —, net income $-5M—Jun ’26Three months to Sep 2026: revenue —, net income $-6M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Monopar Therapeutics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$0 M
Operating income
$-17 M
Net income
$-14 M

For year ending December-2025

Balance sheet

Total assets
$141 M
Total liabilities
$3 M
Total equity
$138 M

As of December-2025

Top 100 institutional investors in Monopar Therapeutics Inc.#

As of Sep 30, 2026
106 institutions held 6.2 M shares (about 91.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 55.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Monopar Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Janus Henderson Group Ltd.1,119,413—16.52%$89 MNov 16, 2026
2Ra Capital Management, L.P.667,2070 (0.00%)9.85%$53 MNov 16, 2026
3BlackRock, Inc.349,244+425 (+0.12%)5.15%$28 MNov 13, 2026
4Saturn V Capital Management LP312,350+374 (+0.12%)4.61%$25 MNov 16, 2026
5Siren, L.L.C.270,1180 (0.00%)3.99%$22 MNov 12, 2026
6State Street Corp229,771+137,220 (+148.26%)3.39%$18 MNov 12, 2026
7Vanguard Capital Management LLC217,958+8,247 (+3.93%)3.22%$17 MNov 13, 2026
8Polar Capital Holdings Plc213,811-658 (-0.31%)3.16%$17 MNov 16, 2026
9Adage Capital Partners GP, L.L.C.209,1950 (0.00%)3.09%$17 MNov 16, 2026
10TCG Crossover Management, LLC202,242-1,085 (-0.53%)2.98%$16 MNov 16, 2026
11ADAR1 Capital Management, LLC179,032-38,563 (-17.72%)2.64%$14 MNov 16, 2026
12Balyasny Asset Management L.P.177,180+42,637 (+31.69%)2.61%$14 MNov 16, 2026
13Wellington Management Group LLP173,645+15,208 (+9.60%)2.56%$14 MNov 16, 2026
14Deerfield Management Company, L.P.137,591-186,154 (-57.50%)2.03%$11 MNov 16, 2026
15Candriam S.C.A.129,797-13,542 (-9.45%)1.92%$10 MNov 3, 2026
16Geode Capital Management, LLC119,852+7,274 (+6.46%)1.77%$10 MNov 6, 2026
17Alyeska Investment Group, L.P.102,228+2,228 (+2.23%)1.51%$8 MNov 16, 2026
18Quadrature Capital Ltd92,499New1.36%$7 MNov 13, 2026
19Vivo Capital, LLC90,5000 (0.00%)1.34%$7 MNov 13, 2026
20Goldman Sachs Group Inc87,877+71,716 (+443.76%)1.30%$7 MNov 16, 2026
21Ikarian Capital, LLC86,761+38,900 (+81.28%)1.28%$7 MNov 16, 2026
22UBS Group AG85,271+58,012 (+212.82%)1.26%$7 MNov 10, 2026
23Driehaus Capital Management LLC84,0400 (0.00%)1.24%$7 MNov 16, 2026
24Bank of New York Mellon Corp74,849-2,093 (-2.72%)1.10%$6 MNov 5, 2026
25Ameriprise Financial Inc50,846+33,046 (+185.65%)0.75%$4 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Monopar Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Millennium Management LLC48,607-1,704 (-3.39%)0.72%$4 MNov 16, 2026
27Citadel Advisors LLC47,896+10,892 (+29.43%)0.71%$4 MNov 16, 2026
28Longaeva Partners L.P.45,720-10,114 (-18.11%)0.67%$4 MNov 16, 2026
29Jane Street Group, LLC43,683New0.64%$3 MNov 12, 2026
30Woodline Partners LP42,960New0.63%$3 MNov 16, 2026
31Vanguard Portfolio Management LLC42,832-5,984 (-12.26%)0.63%$3 MNov 13, 2026
32Morgan Stanley38,037+20,118 (+112.27%)0.56%$3 MNov 13, 2026
33Qube Research & Technologies Ltd37,213New0.55%$3 MNov 13, 2026
34Northern Trust Corp35,190+549 (+1.58%)0.52%$3 MNov 16, 2026
35Vanguard Fiduciary Trust Co31,441+3,161 (+11.18%)0.46%$3 MNov 13, 2026
36Boothbay Fund Management, LLC26,026+11,337 (+77.18%)0.38%$2 MNov 16, 2026
37Deutsche Bank AG\25,461-5,547 (-17.89%)0.38%$2 MNov 6, 2026
38HRT Financial LP23,367New0.34%$2 MNov 13, 2026
39Stempoint Capital LP23,302-6,823 (-22.65%)0.34%$2 MNov 16, 2026
40Two Sigma Investments, LP16,635+4,383 (+35.77%)0.25%$1 MNov 16, 2026
41XTX Topco Ltd15,976+9,440 (+144.43%)0.24%$1 MNov 16, 2026
42D. E. Shaw & Co., Inc.14,723New0.22%$1 MNov 16, 2026
43Charles Schwab Investment Management Inc13,9530 (0.00%)0.21%$1 MNov 16, 2026
44Ishara Investments LP12,000-300 (-2.44%)0.18%$1 MNov 16, 2026
45Bank Of America Corp /de/10,689+7,439 (+228.89%)0.16%$1 MNov 16, 2026
46Engineers Gate Manager LP10,341+6,862 (+197.24%)0.15%$1 MNov 16, 2026
47Verdad Advisers, LP8,409New0.12%$1 MNov 16, 2026
48BNP Paribas Financial Markets8,018+7,277 (+982.05%)0.12%$1 MNov 12, 2026
49Creative Planning7,977+209 (+2.69%)0.12%$1 MNov 2, 2026
50Squarepoint Ops LLC7,738New0.11%$1 MNov 9, 2026
51State Of Wisconsin Investment Board7,351New0.11%$1 MNov 16, 2026
52ExodusPoint Capital Management, LP7,277New0.11%$1 MNov 16, 2026
53Nuveen, LLC7,094+1,114 (+18.63%)0.10%$1 MNov 10, 2026
54Gsa Capital Partners LLP6,706-826 (-10.97%)0.10%$1 MNov 16, 2026
55Rafferty Asset Management, LLC5,959New0.09%$0 MNov 13, 2026
56Magnetar Financial LLC5,777New0.09%$0 MNov 13, 2026
57American Century Companies Inc5,606+3,137 (+127.06%)0.08%$0 MNov 12, 2026
58Gerber, LLC5,6010 (0.00%)0.08%$0 MOct 21, 2026
59Rhumbline Advisers5,600-30 (-0.53%)0.08%$0 MNov 10, 2026
60Virtus Investment Advisers, LLC5,309-165 (-3.01%)0.08%$0 MNov 12, 2026
61State Board Of Administration Of Florida Retirement System5,3000 (0.00%)0.08%$0 MNov 13, 2026
62Trexquant Investment LP4,957-7,047 (-58.71%)0.07%$0 MNov 16, 2026
63Jpmorgan Chase & Co3,979+1,473 (+58.78%)0.06%$0 MNov 12, 2026
64Price T Rowe Associates Inc /MD/3,6990 (0.00%)0.05%$0 MNov 16, 2026
65MetLife Investment Management, LLC2,9080 (0.00%)0.04%$0 MNov 16, 2026
66MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.2,620+544 (+26.20%)0.04%$0 MNov 16, 2026
67Axq Capital, LP2,566New0.04%$0 MNov 12, 2026
68Citigroup Inc2,462+374 (+17.91%)0.04%$0 MNov 4, 2026
69New York State Common Retirement Fund2,4000 (0.00%)0.04%$0 MNov 17, 2026
70Persistent Asset Partners Ltd1,899+628 (+49.41%)0.03%$0 MNov 13, 2026
71Barclays PLC1,893-3,940 (-67.55%)0.03%$0 MNov 6, 2026
72Vanguard Global Advisers, LLC1,845+292 (+18.80%)0.03%$0 MNov 13, 2026
73Meeder Asset Management Inc1,651+262 (+18.86%)0.02%$0 MNov 10, 2026
74Quarry LP1,500-2 (-0.13%)0.02%$0 MNov 16, 2026
75Russell Investments Group, Ltd.1,451-13,399 (-90.23%)0.02%$0 MNov 6, 2026
76Public Employees Retirement System Of Ohio1,410New0.02%$0 MNov 16, 2026
77Police & Firemen's Retirement System of New Jersey1,121-347 (-23.64%)0.02%$0 MNov 9, 2026
78Wells Fargo & Company/mn1,099-2,859 (-72.23%)0.02%$0 MNov 16, 2026
79Tower Research Capital LLC (TRC)936+591 (+171.30%)0.01%$0 MNov 16, 2026
80NewEdge Advisors, LLC6000 (0.00%)0.01%$0 MNov 13, 2026
81FMR LLC578+48 (+9.06%)0.01%$0 MNov 10, 2026
82Legal & General Group Plc425-40 (-8.60%)0.01%$0 MNov 16, 2026
83Ameritas Investment Partners, Inc.4090 (0.00%)0.01%$0 MNov 13, 2026
84Royal Bank Of Canada362+226 (+166.18%)0.01%$0 MNov 16, 2026
85Allworth Financial LP117+6 (+5.41%)0.00%$0 MNov 17, 2026
86Sterling Capital Management LLC104+32 (+44.44%)0.00%$0 MOct 22, 2026
87C M Bidwell & Associates LTD940 (0.00%)0.00%$0 MNov 17, 2026
88California State Teachers Retirement System620 (0.00%)0.00%$0 MNov 13, 2026
89Superior Planning, LLC42—0.00%$0 MNov 12, 2026
90GAMMA Investing LLC39+14 (+56.00%)0.00%$0 MOct 8, 2026
91Arax Advisory Partners32+29 (+966.67%)0.00%$0 MNov 12, 2026
92Global Retirement Partners, LLC320 (0.00%)0.00%$0 MNov 10, 2026
93Osaic Holdings, Inc.24New0.00%$0 MNov 12, 2026
94Farther Finance Advisors, LLC240 (0.00%)0.00%$0 MOct 8, 2026
95US Bancorp \de\21+15 (+250.00%)0.00%$0 MNov 5, 2026
96Parkside Financial Bank & Trust13New0.00%$0 MOct 27, 2026
97PNC Financial Services Group, Inc.7+1 (+16.67%)0.00%$0 MNov 6, 2026
98Jones Financial Companies Lllp7New0.00%$0 MNov 13, 2026
99SJS Investment Consulting Inc.6New0.00%$0 MOct 26, 2026
100Fortitude Family Office, LLC5New0.00%$0 MOct 14, 2026

All 106 institutional investors, with who bought and sold →

Mutual funds holding Monopar Therapeutics Inc.#

86 funds hold shares worth $59 M (about 9.7% of the company). Since their previous reports 40 added shares and 28 sold, buying $1 M net.
Mutual funds holding Monopar Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.159,786$15 M2.4%<0.01%−4.9%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors118,700$11 M1.8%0.01%+8.5%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC49,332$5 M0.73%0.02%+13%Jul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.44,311$4 M0.65%<0.01%−0.4%Jun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors31,751$3 M0.47%0.02%newJun 30, 2026
🇺🇸 BNY Mellon Small/Mid Cap Growth FundBNY Mellon Investment Funds I23,890$2 M0.35%0.25%−8.9%Jun 30, 2026
🇺🇸 Neuberger Small Cap Growth FundNeuberger Berman Investment Advisers LLC25,313$2 M0.37%0.24%+27%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.22,728$1 M0.34%<0.01%+0.6%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors15,148$1 M0.22%0.09%+36%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC20,497$1 M0.30%<0.01%−1.5%May 31, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.19,767$1 M0.29%0.07%+0.1%May 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.10,953$1 M0.16%0.02%+15%Jul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors10,465$1 M0.15%<0.01%−70%Jun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC7,737$1 M0.11%0.01%no changeJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC5,980$1 M0.09%0.02%+7.7%Jul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC7,192$0 M0.11%<0.01%no changeMay 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC4,914$0 M0.07%0.01%+0.7%Jun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC4,745$0 M0.07%0.02%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC5,952$0 M0.09%<0.01%+3.4%May 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.3,000$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation3,000$0 M0.04%0.01%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC4,095$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.4,092$0 M0.06%0.02%−2.4%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.2,647$0 M0.04%<0.01%−14%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC2,170$0 M0.03%0.02%+11%Jul 31, 2026
🇺🇸 Gabelli Healthcare & WellnessRx TrustGabelli Funds, LLC2,500$0 M0.04%0.15%newJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC2,123$0 M0.03%<0.01%+5.5%Jul 31, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC2,430$0 M0.04%0.01%+136%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.2,190$0 M0.03%0.01%+19%Jun 30, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.3,112$0 M0.05%0.02%−35%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.2,105$0 M0.03%<0.01%−28%Jun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.1,724$0 M0.03%<0.01%+71%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC1,452$0 M0.02%<0.01%+6.2%Jul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC1,680$0 M0.02%<0.01%+500%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC1,622$0 M0.02%0.01%+67%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC1,532$0 M0.02%0.01%no changeJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.1,500$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Spectrum FundMeeder Asset Management, Inc.1,389$0 M0.02%0.05%+118%Jun 30, 2026
🇺🇸 BNY Mellon Small Cap Multi-Strategy FundBNY Mellon Investment Adviser, Inc.1,887$0 M0.03%0.09%−13%May 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC1,267$0 M0.02%0.05%no changeJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC1,184$0 M0.02%0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company1,590$0 M0.02%<0.01%−22%May 31, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.920$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC1,058$0 M0.02%<0.01%−68%Jun 30, 2026
🇺🇸 Multi-Manager U.S. Small Cap Equity FundGoldman Sachs Asset Management, L.P.1,865$0 M0.03%0.03%—Apr 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,009$0 M0.01%0.04%+26%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS932$0 M0.01%0.01%no changeJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust1,318$0 M0.02%<0.01%+42%May 31, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC922$0 M0.01%0.01%+14%Jun 30, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC859$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC1,448$0 M0.02%0.05%—Mar 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.708$0 M0.01%0.01%+15%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC595$0 M<0.01%0.02%+0.3%Jul 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC593$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.679$0 M0.01%0.01%+34%Jun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC608$0 M<0.01%0.01%no changeJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC519$0 M<0.01%0.02%no changeJul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC586$0 M<0.01%0.01%+17%Jun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.479$0 M<0.01%<0.01%−4.8%Jul 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC520$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS383$0 M<0.01%0.02%no changeJul 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION600$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management409$0 M<0.01%0.01%+36%Jun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC337$0 M<0.01%0.01%no changeJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC307$0 M<0.01%0.01%+2.7%Jun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.420$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC286$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC229$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC255$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS200$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC178$0 M<0.01%<0.01%−40%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC177$0 M<0.01%<0.01%−69%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC208$0 M<0.01%<0.01%+5.6%May 31, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC144$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC142$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC163$0 M<0.01%<0.01%−42%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC162$0 M<0.01%<0.01%−42%May 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC108$0 M<0.01%<0.01%−2.7%Jun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.105$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC103$0 M<0.01%<0.01%−71%Jun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC88$0 M<0.01%<0.01%−72%Jul 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC96$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC135$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.50$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC28$0 M<0.01%<0.01%+3.7%Jul 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors19$0 M<0.01%<0.01%−5.0%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 86 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Monopar Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$105 K
1 purchase, 1 insider
Sold, 12 months
$4.9 M
27 sales, 6 insiders
Net, 12 months
-$4.8 M
open market only
Insiders on file
16
since
$105 K-$35.0 M$0May 2024: bought $23 K (3 trades), sold $0 (0 trades)May 24Jun 2024: bought $77 K (7 trades), sold $0 (0 trades)Oct 2024: bought $0 (1 trades), sold $0 (0 trades)OctApr 2025: bought $0 (0 trades), sold $1.2 M (1 trades)Jul 2025: bought $0 (0 trades), sold $1.0 M (3 trades)JulSep 2025: bought $0 (0 trades), sold $35.0 M (1 trades)Dec 2025: bought $105 K (1 trades), sold $344 K (2 trades)DecAug 2026: bought $0 (0 trades), sold $807 K (10 trades)Sep 2026: bought $0 (0 trades), sold $2.6 M (4 trades)SepOct 2026: bought $0 (0 trades), sold $659 K (3 trades)Nov 2026: bought $0 (0 trades), sold $505 K (8 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Monopar Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Kim R. TsuchimotoDirectorOption exercise10b5-1 plan+856$30.00$26 K856Form 4
filed Kim R. TsuchimotoDirectorOption exercise10b5-1 plan+2,035$14.00$28 K2,891Form 4
filed Kim R. TsuchimotoDirectorSell10b5-1 plan-1,295$70.75$92 K1,596Form 4
filed Kim R. TsuchimotoDirectorSell10b5-1 plan-996$71.35$71 K600Form 4
filed Kim R. TsuchimotoDirectorSell10b5-1 plan-600$72.21$43 K0Form 4
filed Kim R. TsuchimotoDirectorOption exercise10b5-1 plan+1,199$30.00$36 K1,199Form 4
filed Raymond AndersonDirectorOption exercise10b5-1 plan+1,402$30.00$42 K6,775Form 4
filed Raymond AndersonDirectorOption exercise10b5-1 plan+1,740$30.00$52 K8,515Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Monopar Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.1 M
16.5% of shares · 8.8 days to cover
Buybacks, Q4 2025
$0M
Q4 2025
Shares sold short, last 24 reportsAll stocks →
Monopar Therapeutics Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2025Q4 2025$0M
Q4 2024Q4 2025$0M

Fails to deliver

  • : 106 shares at $71.84
  • : 3,571 shares at $72.58
  • : 3,431 shares at $72.35
  • : 2,628 shares at $74.23
  • : 1,507 shares at $116.28

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Monopar Therapeutics Inc. scorecard#

Passes 2 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation0 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.5×Price to book 3.5× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$14 M-$14 M in fiscal 2025 against -$6 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$14 MNet income -$14 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-14.2%-14.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities51.3×Current ratio 51.26 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • ✓Dividends and buybacks above 3% of the market value7.2%Dividends and buybacks were 7.2% of the market value.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Monopar Therapeutics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Monopar Therapeutics Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue00————0000
Research and development9.9135.67.66.54.12.01.80.90.3
General and administrative6.83.23.22.92.62.42.41.6r1.20.9
Operating expenses17168.8119.16.54.33.3r171.2
Operating income−17−16−8.8−11−9.1−6.5−4.3−3.3r−17−1.2
Interest and finance income3.00.40.4———————
Net interest income——0.40.00.00.10.10.10.00.0
Income before tax−14−16−8.4————−3.3−17—
Income tax0.00.00.00.0r00.00−0.1−0.00.0
Net income including minority interests———−11−9.1—————
Net income attributable to shareholders−14−16−8.4−11−9.1−6.3−4.2−3.2−17−1.2
Earnings per share, basic-1.85-4.11-3.04r-0.83-0.73-0.58-0.45-0.35-1.89—
Earnings per share, diluted————-0.73-0.58-0.45-0.35-1.89—
Shares, weighted average (basic)7.43.82.8r1312—————
Shares, weighted average (diluted)————12119.39.38.8—
Balance sheet
Cash and cash equivalents62467.38.22017136.99.02.1
Short-term investments61466.512——————
Other current assets0.10.10.10.00.20.10.0———
Current assets140607.3132117137.3r9.12.1
Right-of-use (leased) assets0.300.00.10—————
Total assets141607.3132117137.39.92.9
Accounts payable2.72.31.83.11.61.20.70.40.30.1
Current liabilities2.75.31.83.11.61.20.70.40.30.1
Lease liabilities (non-current)0.2000.00—————
Non-current liabilities——————0000
Total liabilities2.95.31.83.11.61.20.70.40.30.1
Retained earnings−90−76−60−52−41−32−26−22r−18−1.9
Shareholders' equity138555.6101916136.99.62.8
Total liabilities and equity141607.3132117137.39.92.9
Shares outstanding6.76.13.0r131311119.39.3—
Cash-flow statement
Share-based compensation4.81.11.91.61.51.31.00.50.30
Cash from operating activities−12−6.4−7.9−7.2−7.3r−4.7−3.0−2.7r−2.6−1.2
Cash from investing activities−63−144.9−4.90—————
Shares issued04.22.10.1—8.2004.70
Shares bought back−350————————
Cash from financing activities92592.00.0118.29.3−0.2r9.51.3
Exchange-rate effect on cash—————0.0−0.0−0.00—
Change in cash1639−0.9−123.63.56.3−2.96.90.1
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Monopar Therapeutics Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$10.6 M
Chandler Robinson
Other top executives, average
$2.3 M
the CEO earned 4.6× this
$100 invested is now
$3839
Monopar Therapeutics Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chandler Robinson$10.6 M$17.4 M$2.3 M$3839
2024Chandler Robinson$1.1 M$2.4 M$437 K$186
2023Chandler Robinson$1.8 M−$166 K$880 K$14

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Monopar Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 4 · New debt 1 · Unregistered share sale 2 · Shareholder vote 2 · Results announced 9

Monopar Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Material agreement8-K
Acquisition or sale completedMaterial agreementNew debtUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Monopar Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2015$2 MNo. 1$2 to $10 million8equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Monopar Therapeutics Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $98 K a year.

Certified, FY2026
1
#1,917 among companies on value.today
Worker positions
1
Median wage offered
$98 K
a year, full-time
Applications filed
3
Monopar Therapeutics Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
CMC Operations AssociateLogisticians1$98 K

Where: Wilmette, IL 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Monopar Therapeutics Inc

Discuss Monopar Therapeutics Inc.#

3 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 12 November 2026automatic update · Nov 12, 2026

    Monopar Therapeutics Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $6 million.

  • Insider trading in October 2026automatic update · Oct 31, 2026

    Directors and officers of Monopar Therapeutics Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 1 insider sold shares worth about $659,387 in 3 trades. Awards, option exercises and shares withheld for tax are not counted.

  • Mutual funds: 86 funds hold $59 millionautomatic update · Jul 31, 2026

    86 mutual funds in 1 country hold shares of Monopar Therapeutics Inc. worth $59 million, about 9.7% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 40 funds added shares and 28 sold; on balance they bought $560,000. Share splits are not counted as trading.

How Monopar Therapeutics Inc. compares in Biotechnology

  • Market cap$487 M · higher than 58% of 726
  • Revenue$0 M · higher than 0% of 647
  • Price / book3.5× · lower than 43% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Monopar Therapeutics Inc.🇺🇸$487 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, value.today research, SEC filing, Wikidata, SEC annual report, GLEIF register.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Monopar Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Monopar Therapeutics Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Monopar Therapeutics Inc.? Suggest a correction